author: Previous research
Key takeaways from the 10th Impurity Summit (Milan, March 4-5, 2026)
The 10th Impurities: Genotoxicity, Nitrosamines and Beyond Summit was held on 4th and 5th March 2026 in Milan. The event featured innovative technology trends currently impacting genotoxicity testing and impurity analysis in the pharmaceutical industry. Industry leaders and experts discussed effective ways to improve the detection, analysis, and risk assessment of genotoxic substances in pharmaceuticals. Discussion centered on efficiency, accuracy, and regulatory requirements.
AI-powered impurity profiling: The key to smarter testing decisions
One of the main areas of discussion at the summit was impurity profiling with artificial intelligence. This technology uses chemical information to predict potential impurities with the potential for DNA damage, allowing pharmaceutical laboratories to prioritize in vitro genotoxicity testing. By combining AI predictions with traditional tests such as the Ames test and the micronucleus test, laboratories can focus their testing on the most dangerous substances. Industry experts at the summit noted that AI technology can not only increase the speed and efficiency of testing, but also optimize data quality by reducing the risk of false positives and pointing out subtle indicators of genotoxicity.
Next-generation analytical platform: Identifying trace-level impurities
In addition to AI, the summit also focused on next-generation analytical tools. The application of high-resolution liquid chromatography-mass spectrometry and real-time monitoring systems was highlighted as a means to improve the detection of trace-level impurities. These technologies enable laboratories to perform more comprehensive and reliable testing while meeting stringent regulatory demands, especially in high-throughput environments.
The global genotoxicity testing market size is calculated to be USD 2.26 billion in 2025 and is expected to increase from USD 2.49 billion in 2026 to approximately USD 5.97 billion by 2035. has been measured and is projected to expand at a CAGR of 10.20% from 2026 to 2035 as demand for rapid and accurate testing for chemical and drug-induced genetic damage increases.
Integration of computational approaches
The summit also highlighted the application of in silico and predictive models as an integral part of genotoxicity testing. By applying read-across strategies and Threshold of Toxic Concern (TTC) approaches, scientists can predict the potential genotoxic hazards of compounds for which little or no data are available. Combining these models with AI and high-resolution analytics can also help develop robust hybrid testing workflows.
A recent report by Precedence Research highlights that the genotoxicity testing market is benefiting from the increased use of automated systems to improve the speed and efficiency of genotoxicity testing.
